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Early virological failure and HIV drug 
resistance in Ugandan adults co-infected 
with tuberculosis
Amrei von Braun1,2*, Christine Sekaggya‑Wiltshire1, Alexandra U. Scherrer2, Brian Magambo3, 
Andrew Kambugu1, Jan Fehr2 and Barbara Castelnuovo1
Abstract 
Purpose: This cross‑sectional study took place in the integrated tuberculosis (TB) clinic of a large outpatient clinic 
for HIV‑infected patients in Kampala, Uganda. The purpose of this study was to describe the proportion of TB/HIV 
co‑infected adults with virological failure, type and frequency of HIV drug resistance‑associated mutations, and the 
proportion of patients with suboptimal efavirenz levels.
Methods: HIV‑1 plasma viral loads, CD4 cell count measurements, and efavirenz serum concentrations were done in 
TB/HIV co‑infected adults. Genotypic resistance testing was performed in case of confirmed virological failure.
Results: After a median time on ART of 6 months, virological failure was found in 22/152 patients (14.5%). Of 147 
participants with available efavirenz serum concentration, 26 (17.6%) had at least one value below the reference 
range, including 20/21 (95.2%) patients with confirmed virological failure. Genotypic resistance testing was available 
for 16/22 (72.7%) patients, of which 15 (93.8%) had at least one major mutation, most commonly M184V (81.2%) and 
K103NS (68.8%).
Conclusion: We found a high proportion of TB/HIV co‑infected patients with virological failure, the majority of which 
had developed relevant resistance‑mutations after a median time on anti‑retroviral treatment (ART) of 6 months. 
Virological monitoring should be prioritized in TB/HIV co‑infected patients in resource‑limited settings.
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Background
In 2013, the World Health Organization (WHO) reported 
47′650 new cases of tuberculosis (TB) in Uganda, making 
it to one of 22 high-burden TB countries [1]. Of all new 
cases reported, 48% of the individuals were co-infected 
with Human Immunodeficiency Virus (HIV). Despite 
considerable improvements in care for both infections, 
such as enhanced access and earlier initiation of antiret-
roviral treatment (ART), as well as intensified TB case 
finding strategies, TB remains the leading cause of death 
among HIV-infected individuals in sub-Saharan Africa 
[2]. The main challenges in management of co-infection 
with Mycobacteria tuberculosis and HIV could be attrib-
uted to overlapping toxicities and drug–drug interaction 
[3], immune reconstitution inflammatory syndrome [4], 
costly treatment monitoring, and difficulties in adher-
ence [5].
In resource-limited settings such as Uganda, close 
treatment monitoring strategies as optimally required for 
both infections are not readily available for all patients. 
For financial reasons, virological monitoring of HIV-
infected patients on ART has either not been available 
or is reserved for selected patients (targeted viral loads), 
such as patients with diagnosed immunological failure 
[6]. While CD4 cell counts are available to patients free of 
charge, at the time of this study the facility price per viral 
load was approximately 60USD in Kampala.
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In the absence of routine or targeted viral load test-
ing, the WHO recommends to monitor ART using CD4 
count testing [7], although immunologic criteria for 
treatment failure have a low sensitivity and positive pre-
dictive value for the detection of patients with virologi-
cal failure [8]. Especially when TB co-infection is present, 
the interpretation of clinical and immunological findings 
while monitoring HIV-infected patients is challenging 
[9–11]. Individual patient HIV drug resistance testing is 
not routinely available due to its high costs.
Evidence of reduced morbidity and mortality sup-
ports early initiation of ART in TB co-infected patients 
[12]. According to WHO treatment recommendations 
[7], TB/HIV co-infected patients are preferably initiated 
on an efavirenz-based regimen within the first 8  weeks 
of TB treatment, due less drug–drug interactions when 
co-administered with rifampicin-based TB treatment and 
well-demonstrated efficacy [1].
So far, little information is available on early virologi-
cal outcomes of TB/HIV co-infected patients on ART, 
and the development of HIV drug resistance in those 
with viral failure. The objective of this study was to assess 
the proportion of TB/HIV co-infected Ugandan patients 
with virological failure, identify factors potentially associ-
ated with treatment failure, and to report type and fre-
quency of HIV drug resistance mutations detected in TB/
HIV co-infected patients failing ART.
Methods
This cross-sectional study was conducted at the inte-
grated TB/HIV clinic of the Infectious Diseases Insti-
tute (IDI) in Kampala, Uganda, between April 2013 and 
2015. The IDI currently provides care for over 8000 
HIV-infected individuals. In the integrated TB clinic [13] 
approximately 300 cases of TB are diagnosed annually. At 
the time of this study, patients on ART were monitored 
with CD4 count measurements, although targeted viral 
load testing was available.
This study was a sub-study of the ongoing “Study on 
Outcomes related to tuberculosis and HIV drug con-
centrations in Uganda” (SOUTH study), which inves-
tigates the association between TB treatment outcome 
and serum concentrations of anti-TB drugs in TB/HIV 
co-infected Ugandan adults (ClinicalTrials.gov Identi-
fier: NCT01782950). Participants included in the study 
were HIV-infected adults of 18 years and above, receiv-
ing treatment with rifampicin, isoniazid, pyrazina-
mide, ethambutol for 8  weeks, followed by 16  weeks of 
rifampicin/isoniazid for newly diagnosed pulmonary TB 
[14]. Efavirenz-based ART was started two to four weeks 
after initiation of TB treatment in previously ART-naïve 
patients. ART experienced patients on nevirapine-based 
ART at time of TB diagnosis were switched to efavirenz 
[14].
HIV type 1 plasma viral load measurements were 
performed as soon as a patient had been on ART for at 
least 6  months, accompanied by simultaneously meas-
ured CD4 cell count. Viral load measurements (COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0, Roche 
Diagnostics) and CD4 cell counts (BD FACSCalibur Flow 
Cytometer: 4-Color) were performed at the Makerere-
University-John-Hopkins-University (MUJHU) CORE 
laboratory certified by the College of American Pathol-
ogists, located at the IDI. For patients receiving efa-
virenz-based ART, efavirenz serum concentrations were 
measured on-site, 9–15  h post-dosing using a validated 
ultra-violet high-performance liquid chromatography 
(UV-HPLC) method at week 8 and 24 of TB treatment. 
Patients with confirmed virological failure received gen-
otypic drug resistance testing performed at the Ugan-
dan Virus Research Institute/Medical Research Council 
(UVRI/MRC) in Entebbe, Uganda, (Method: PCR gel 
electrophoresis and purification (QIAquick PCR puri-
fication kit), sequencing (Big dye terminator v3.1 cycle 
sequencing kit, Applied Biosystems), genetic analysis 
(ABI 3500 and ABI 3130 machines, Applied Biosystems), 
base-called sequences (Sequencher v5.3 and sequence 
alignments, BioEdit v7.2.5 and SeaView v4.0), quality 
assurance (Calibrated Population Resistance tool, Stan-
ford and the Los Alamos National database for the HIV 
Sequence Quality Analysis), and assigning of drug resist-
ance mutations (submission of sequences to Stanford 
HIVdb Program).
Virological failure was defined as one HIV-1 plasma 
viral load  >1000 copies/ml or two consecutive viral 
loads  >400 copies/ml within three months. Favorable 
outcome of TB treatment was defined as fulfilling the 
WHO criteria of either cured or completed treatment 
[14]. History of HIV-infection, past and current ART 
regimens, and previous CD4 cell counts were derived 
from the routine electronic medical records and study 
case report forms. Characteristics of patients with viro-
logical treatment failure were compared to patients with-
out treatment failure. Proportions were compared using 
Fisher’s exact test and medians using Wilcoxon rank-sum 
test.
Results
During the study period, one hundred and fifty-two indi-
viduals were enrolled in this study. The median age was 
34  years (interquartile range (IQR): 28–39) and 58.6% 
of the study participants were male. The majority was 
ART-naïve at time of TB diagnosis (110, 72.4%) and they 
were initiated on efavirenz-based ART two to four weeks 
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after starting TB treatment. The median CD4 cell count 
at time of viral load measurement was 285 cells/µl (IQR: 
150–453).
The most common ART regimen at time of viral load 
measurement consisted of tenofovir, lamivudine and 
efavirenz (119 patients, 78.3%), followed by zidovudine, 
lamivudine and efavirenz (29 patients, 19.1%). Only four 
patients (2.6%) were on second-line treatment with teno-
fovir, lamivudine and either ritonavir-boosted atazanavir 
or ritonavir-boosted lopinavir. Of all patients enrolled, 30 
(19.7%) had previously substituted at least one antiretro-
viral drug, mainly due to TB co-infection.
Viral load measurements were performed after a 
median time on ART of 6 months (IQR: 5.5–12). Virolog-
ical failure was found in 22/152 (14.5%) patients, with a 
median viral load log10 of 4.6 copies/ml (IQR: 4.0–5.3). Of 
patients with virological failure, 11 (50%) had been ART-
naïve at TB diagnosis. Table 1 compares characteristics of 
patients with and without virological failure. There was 
no difference in ART regimens between the two groups, 
however, a higher proportion of patients with virological 
failure had one or more antiretroviral drug substitution 
in the past as compared to patients with no virologic fail-
ure (history of ART substitution: 36.4 vs. 17.0%, p value: 
0.044).
Generally, TB treatment outcome was favorable in our 
study population with 142 (93.4%) patients being cured 
or completed treatment. However, a lower proportion of 
patients with virological failure had a favorable TB treat-
ment outcome (77.3%) as compared to patients with viral 
suppression (96.2%) (p value: 0.004).
A total of 148 participants were on efavirenz-based 
ART, of which 147 had available efavirenz serum con-
centration. Of these, 26 (17.7%) had at least one efavirenz 
serum concentration below the reference range of 1 mg/l; 
a significantly higher proportion of patients with con-
firmed virological failure (95.2%) had a serum concentra-
tion below the reference range as compared to patients 
with viral suppression.
Of the 22 patients with virological failure, 16 (72.7%) 
underwent genotypic resistance testing. The remaining 
6 patients were either lost-to-follow-up (2 patients), had 
died (2 patients), or were switched to second-line treat-
ment before resistance testing could be done (2 patients). 
HIV subtype distribution of these 16 patients was as fol-
lows: subtype A, C, D and recombinant were 3, 1, 3, and 
8 patients respectively. Among recombinant HIV strains 
we found 5 CRF and 3 A/D. As shown in Table 2, geno-
typic resistance testing revealed that 15 of 16 (93.8%) 
patients had developed one or more relevant resistance 
mutations to first-line drugs commonly used in Uganda. 
The most common mutations found were M184V (81.2%) 
reflecting treatment with the nucleoside/nucleotide 
reverse transcriptase inhibitor (NRTI) lamivudine, and 
K103NS (68.8%) reflecting prior treatment with the non-
nucleoside reverse transcriptase inhibitors (NNRTI) 
Table 1 Characteristics of  tuberculosis (TB)/HIV co-infected patients stratified by  virological outcome with  and with-
out virological failure
TDF tenofovir, 3TC lamivudine, EFV efavirenz, AZT zidovudine, ATV/r ritonavir-boosted atazanavir, LPV/r ritonavir-boosted lopinavir, Immunological failure drop of CD4 
cell count to or below baseline, Virological failure HIV plasma viral load >1000 copies/ml or two consecutive viral loads >400/ml within 3 months
Characteristics All patients n = 152 Viral suppression n = 130 Virological failure n = 22 P value
Male gender [N, %] 89 (58.6) 80 (61.5) 9 (40.9) 0.099
Age (years) [Median, IQR] 34.1 (27.0–39.4) 34 (28.3–38.9) 34.1 (25.2–40.9) 0.882
CD4 cell count (cells/µl) [Median, IQR] 285 (150–453) 317 (170–465) 130 (43–341) <0.001
Time on ART (months) [Median, IQR] 6 (5.5–12) 6 (5.5–11) 6 (5–24) 0.157
ART regimen [N, %] 0.194
 TDF‑3TC‑EFV 119 (78.3) 105 (80.8) 14 (63.6)
 AZT‑3TC‑EFV 29 (19.1) 22 (16.9) 7 (31.8)
 TDF‑3TC‑ATV/r 3 (1.9) 2 (1.5) 1 (4.6)
 TDF‑3TC‑LPV/r 1 (0.7) 1 (0.8) 0
History of ART switch [N, %] 30 (19.7) 22 (17) 8 (36.4) 0.044
Immunological failure [N, %] 21 (13.8) 10 (7.7) 11 (50) <0.001
EFV serum concentration <1 mg/l [N/, %] 26 (17.7) 6 (4.8) 20 (95.2) <0.001
 TB outcome [N, %] 0.004
 Cured/completed 142 (93.4) 125 (96.2) 17 (77.3)
 Failure 3 (2.0) 1 (0.8) 2 (9.1)
 Died 2 (1.3) 2 (1.5) 0
 Unknown 5 (3.3) 2 (1.5) 3 (13.6)
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nevirapine or efavirenz. Furthermore, 13/16 (81.3%) 
patients had developed two drug class resistance muta-
tions to both NNRTI and NRTI, while only 2/16 (12.5%) 
had developed resistance mutations to only one drug 
class (NNRTI). Major resistance mutations to protease 
inhibitors were not observed in our study population. 
One patient on second-line treatment underwent resist-
ance testing which revealed resistance to NNRTI only.
Discussion
Among our population of Ugandan TB/HIV co-infected 
adults on ART and TB treatment we found a high pro-
portion (14.5%) of patients with virological failure after 
a median time on ART of 6  months. A similarly high 
proportion of treatment failure was previously observed 
among TB/HIV co-infected patients from India [15, 16]. 
However, the proportion of virological failure among 
patients without TB at our clinic was much lower 
(7.95%) [17]. Furthermore, the majority of patients pre-
sented here had already developed two-class drug resist-
ance which strongly limits their treatment options in a 
resource-limited setting such as Uganda. TB treatment 
outcome overall was favorable, but a significantly smaller 
proportion of patients with virological failure was either 
cured or completed TB treatment as compared to viro-
logically suppressed patients.
The majority of patients with virological failure on 
efavirenz-based ART had at least one efavirenz serum 
concentration below reference range during concomitant 
TB treatment. Efavirenz levels below reference range are 
a risk factor for virological failure and the development 
of resistance-associated mutations [18]. Although phar-
macokinetic aspects such as drug–drug interactions [3] 
as well as pharmacogenetic factors [19, 20] can reduce 
efavirenz concentrations, it seems that in our population 
poor adherence was a major contributing factor to low 
efavirenz levels considering the fact that a lower propor-
tion of patients with virological failure had a favorable TB 
outcome compared to virological suppressed patients. 
This suggests this patient group may have been overall 
less compliant to both ART and TB treatment.
Reasons for poor adherence are diverse in TB/HIV 
co-infected patients and include large pill burden and 
significant side effects, as well as factors affecting non-
TB-infected HIV-positive patients such as stigma or dis-
belief. As TB in sub-Saharan Africa disproportionately 
affects the economically most disadvantaged members 
of society [21], additional financial burdens due to lost 
wages through illness and frequent clinic visits as well as 
long distances to care centers may further challenge opti-
mal adherence in this patient group.
Only 50% of patients with virological failure also had 
immunologic failure. Thus, in the absence of virologi-
cal monitoring, treatment failure would not have been 
detected in these patients. Patients with undetected 
treatment failure are at risk of further accumulation of 
resistance mutations, which complicates future treat-
ment in a setting with limited antiretroviral drug options 
and may contribute to the transmission of drug resistant 
viruses to partners. In our study population, the major-
ity of patients with virological failure had already devel-
oped relevant resistance mutations after a median time 
on ART of 6 months. Among patients with available data 
on HIV drug resistance, 15/16 (93.8%) required switching 
to second-line drugs due to resistance-associated muta-
tions. Most strikingly, the majority of the patients had 
developed two class drug resistance to both NNRTI and 
Table 2 Type and  frequency of  resistance-associated 
mutations detected in 16 patients with virological failure
NRTI nucleoside/nucleotide reverse transcriptase inhibitors, TAM thymidine 
analogue mutations, NNRTI non-nucleoside/nucleotide reverse transcriptase 
inhibitors, PI protease inhibitor
Mutations N (%)
Any major mutation 15 (93.8)
Any NRTI mutation 13 (81.2)
Any TAM 5 (31.3)
3 or more TAMs 3 (18.8)
M41L 2 (12.5)
K65R 4 (25.0)
D67N 2 (12.5)
K70R 2 (12.5)
K70E 1 (6.3)
L74V/I 1 (6.3)
Y115F 1 (6.3)
M184IV 13 (81.2)
L210W 1 (6.3)
T215FY 2 (12.5)
K219GE 4 (25)
NNRTI major mutations
 Any major mutation 15 (93.8)
 L100I 0
 K101PEH 3 (18.8)
 K103NS 11 (68.8)
 V106AM 1 (6.3)
 E138KAGQ 2 (12.5)
 V179DEF 1 (6.3)
 Y181CIV 1 (6.3)
 Y188LCH 1 (6.3)
 G190ASEQ 5 (31.3)
 F227LC 0
 M230L 4 (25)
PI mutations
 Minor 9 (56.3)
 Major 0
Page 5 of 6von Braun et al. AIDS Res Ther  (2017) 14:1 
NRTI, which greatly limits optimal treatment choices in 
this setting. M184 V and K103NS were the most preva-
lent mutations found, reflecting prior treatment with 
lamivudine, efavirenz or nevirapine. Major PI mutations 
were not observed in any of the participants.
Partly, our study findings are limited by the fact that 
HIV drug resistance tests were not performed before the 
initiation ART and, therefore, information on transmit-
ted drug resistance was not available. However, so far 
pre-treatment HIV drug resistance seems to be low in 
Uganda [22].
Conclusion
In conclusion, based on our study finding of a high pro-
portion of TB/HIV co-infected patients with virologi-
cal failure and selection of relevant resistance mutations 
after only 6  months on ART, we recommend that viro-
logical monitoring should be prioritized in TB/HIV co-
infected patients in resource-limited settings. In addition, 
further efforts are required to address specific adherence 
challenges in TB/HIV co-infected patients.
Abbreviations
HIV: Human Immunodeficiency Virus; TB: tuberculosis; ART: anti‑retroviral 
treatment; WHO: World Health Organization; IDI: Infectious Diseases Institute; 
SOUTH study: Study on Outcomes related to Tuberculosis and HIV drug con‑
centrations in Uganda; MUJHU: Makerere‑University‑John‑Hopkins‑University; 
UV‑HPLC: ultra‑violet high‑performance liquid chromatography; UVRI/MRC: 
Ugandan Virus Research Institute/Medical Research Council; IQR: interquartile 
range; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non‑nucleoside 
reverse transcriptase inhibitors.
Authors’ contributions
AB designed and conducted this sub‑study, and prepared the manuscript. CS 
assisted greatly in conducting the study, and contributed substantially to the 
writing of the manuscript. AUS did the statistical analyses presented here and 
edited the manuscript. BM performed the resistance testing shown here and 
contributed to the writing of the manuscript. AK kindly reviewed and edited 
this manuscript. The scientific input was provided by BC and JF, who super‑
vised this study and contributed equally to the writing of the manuscript. All 
authors read and approved the final manuscript.
Author details
1 Infectious Diseases Institute, College of Health Sciences, Makerere University, 
Kampala, Uganda. 2 Division of Infectious Diseases and Hospital Epidemiol‑
ogy, University Hospital of Zurich, University of Zurich, Rämistrasse 100, 
8091 Zurich, Switzerland. 3 Uganda Research Unit on AIDS, Medical Research 
Council, Ugandan Virus Research Institute, Entebbe, Uganda. 
Acknowledgements
We would like to acknowledge all patients and their families. We especially 
thank Ms. Ritah Nakijoba and the team of the integrated TB/HIV clinic at the 
IDI in Kampala for their dedicated patient care and their contributions to data 
collection. We further thank Mr. Allan Buzibye for performing the efavirenz 
concentration measurements used in this study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are 
available from the corresponding author on reasonable request.
Ethics approval and content to participate
This study was reviewed and approved by the Makerere University Faculty of 
Medicine Research and Ethics Committee (Approval Number: 120‑2009), and 
the Uganda National Council for Science and Technology (HS 683). All study 
participants gave written informed consent prior to study participation.
Funding
Amrei von Braun received a kick‑starting grant from the University of Basel 
Global Affairs Program to conduct this research. The pharmaceutical company 
ROCHE© donated the viral load kits which were used in this study.
Received: 30 October 2016   Accepted: 7 December 2016
References
 1. WHO. Global Tuberculosis Report. 2014.
 2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. 
The growing burden of tuberculosis: global trends and interactions with 
the HIV epidemic. Arch Intern Med. 2003;163(9):1009–21.
 3. Cohen K, Meintjes G. Management of individuals requiring antiretroviral 
therapy and TB treatment. Curr Opin HIV AIDS. 2010;5(1):61–9.
 4. Shankar EM, Vignesh R, Ellegard R, Barathan M, Chong YK, Bador MK, et al. 
HIV‑Mycobacterium tuberculosis co‑infection: a ‘danger‑couple model’ of 
disease pathogenesis. Pathog Dis. 2014;70(2):110–8.
 5. Naidoo P, Peltzer K, Louw J, Matseke G, McHunu G, Tutshana B. Predictors 
of tuberculosis (TB) and antiretroviral (ARV) medication non‑adherence in 
public primary care patients in South Africa: a cross sectional study. BMC 
Public Health. 2013;13:396.
 6. Castelnuovo B, Nsumba M, Musomba R, Kaimal A, Lwanga I, Kambugu 
A, et al. Strengthening the “viral failure pathway”: clinical decision and 
outcomes of patients with confirmed viral failure in a large HIV care clinic 
in Uganda. J Acquir Immune Defic Syndr. 2015;70(5):e174–6.
 7. WHO. Consolidated Guidelines ARV, chapter 7. 2013.
 8. Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, 
Penazzato M, et al. Predicting treatment failure in adults and children on 
antiretroviral therapy: a systematic review of the performance charac‑
teristics of the 2010 WHO immunologic and clinical criteria for virologic 
failure. AIDS. 2014;28(Suppl 2):S161–9.
 9. Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reac‑
tions and immune reconstitution inflammatory syndrome in tuberculosis. 
Int J Infect Dis. 2015;32:39–45.
 10. Ezeamama AE, Mupere E, Oloya J, Martinez L, Kakaire R, Yin X, et al. Age, 
sex, and nutritional status modify the CD4 + T‑cell recovery rate in HIV‑
tuberculosis co‑infected patients on combination antiretroviral therapy. 
Int J Infect Dis. 2015;35:73–9.
 11. Gupta RK, Brown AE, Zenner D, Rice B, Yin Z, Thomas HL, et al. CD4 + cell 
count responses to antiretroviral therapy are not impaired in HIV‑infected 
individuals with tuberculosis co‑infection. AIDS. 2015;29(11):1363–8.
 12. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. 
Timing of antiretroviral therapy for HIV‑1 infection and tuberculosis. N 
Engl J Med. 2011;365(16):1482–91.
 13. Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman 
AI, et al. Integration of HIV and TB services results in improved TB treat‑
ment outcomes and earlier prioritized ART initiation in a large urban HIV 
clinic in Uganda. J Acquir Immune Defic Syndr. 2012;60(2):e29–35.
 14. WHO. Guidelines for treatment of tuberculosis. 4th ed. 2010.
 15. Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S. Antiret‑
roviral drug‑resistant mutations at baseline and at time of failure of 
antiretroviral therapy in HIV type 1‑coinfected TB patients. AIDS Res Hum 
Retroviruses. 2009;25(11):1179–85.
 16. Sinha S, Raghunandan P, Chandrashekhar R, Sharma SK, Kumar S, Dhooria 
S, et al. Nevirapine versus efavirenz‑based antiretroviral therapy regimens 
in antiretroviral‑naive patients with HIV and tuberculosis infections in 
India: a pilot study. BMC Infect Dis. 2013;13:482.
 17. von Braun A, Scherrer AU, Sekaggya C, Kirangwa J, Ssemwanga D, 
Kaleebu P, Günthard H, Kambugu A, Castelnuovo B, Fehr J. High rates of 
multi class drug resistance in HIV‑1 infected individuals monitored with 
CD4 count in Uganda. HIV Glasgow: Abstract; 2016.
Page 6 of 6von Braun et al. AIDS Res Ther  (2017) 14:1 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 18. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of 
HIV. J Antimicrob Chemother. 2009;64(5):910–28.
 19. Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co‑
infection: a practical therapeutic approach. Drugs. 2006;66(18):2299–308.
 20. Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen 
S, Nilkamhang S, et al. CYP2B6 haplotype and biological factors responsi‑
ble for hepatotoxicity in HIV‑infected patients receiving efavirenz‑based 
antiretroviral therapy. Int J Antimicrob Agents. 2014;43(3):292–6.
 21. Barter DM, Agboola SO, Murray MB, Barnighausen T. Tuberculosis and 
poverty: the contribution of patient costs in sub‑Saharan Africa—a 
systematic review. BMC Public Health. 2012;12:980.
 22. Lee GQ, Bangsberg DR, Muzoora C, Boum Y, Oyugi JH, Emenyonu N, et al. 
Prevalence and virologic consequences of transmitted HIV‑1 drug resist‑
ance in Uganda. AIDS Res Hum Retroviruses. 2014;30(9):896–906.
